25+ Key Opinion Leaders (KOLs) were contacted for insights on Glucagon-like Peptide-1 (GLP-1) Agonists incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility
Always has the alarm bells for me
o Discontinue if eGFR falls below 30 mL/min/1.73 m2
Apart from stimulating the secretion of either insulin or glucagon in glucose-dependent manner [33], GIP promotes lipogenesis and lipid deposition under conditions of hyperinsulinema [34,35,36] while stimulating lipolysis and fatty acid oxidation under conditions of normo- or hypoinsulinemia [37,38,39]
Each injection session is quick and easy, typically administered at a healthcare facility, though some patients may be trained to self-administer the injection at home after their first few sessions
H.RemmeN.HabelA.ChankhamjonP.ScherlachK.HeinekampT.et al (2011)